Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
KIBRA CRISPR/Cas9 KO Plasmid (h): sc-402677
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- KIBRA CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the KIBRA genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: KIBRA Antibody (B-3): sc-518263
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
KIBRA CRISPR/Cas9 KO Plasmid (h) | sc-402677 | 20 µg | $397.00 |
Overview
WWC1 encodes KIBRA, a WW-domain–containing scaffold protein enriched in brain and kidney that coordinates protein–protein interactions via its WW and C2 domains. KIBRA participates in Hippo pathway regulation through interactions with LATS kinases and related components, linking cell polarity, contact inhibition, and transcriptional control of proliferation and apoptosis. It also interfaces with membrane trafficking and cytoskeletal remodeling pathways, supporting processes such as endocytosis and directed migration. Dysregulated WWC1/KIBRA signaling has been associated with alterations in synaptic plasticity and has been investigated in the context of cancer-relevant growth control and neurobiology.
KIBRA CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the WWC1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the WWC1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the WWC1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish KIBRA protein expression.
This CRISPR knockout system enables efficient generation of WWC1-deficient cell models for investigation of KIBRA signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting WWC1 exon(s) critical for KIBRA function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple WWC1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by KIBRA CRISPR/Cas9 KO Plasmid (h) and KIBRA CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the WWC1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by KIBRA HDR Plasmid (h) and KIBRA HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by WWC1 homology arms to support homology-directed repair at defined WWC1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.